- Home
- ARQQ vs NYXH Comparison
ARQQ vs NYXH Comparison
Compare ARQQ & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQQ
- NYXH
- Stock Information
- Founded
- ARQQ 2017
- NYXH 2009
- Country
- ARQQ United Kingdom
- NYXH Belgium
- Employees
- ARQQ N/A
- NYXH N/A
- Industry
- ARQQ Computer Software: Prepackaged Software
- NYXH Medical/Dental Instruments
- Sector
- ARQQ Technology
- NYXH Health Care
- Exchange
- ARQQ Nasdaq
- NYXH Nasdaq
- Market Cap
- ARQQ 194.9M
- NYXH 222.3M
- IPO Year
- ARQQ N/A
- NYXH 2021
- Fundamental
- Price
- ARQQ $15.84
- NYXH $6.30
- Analyst Decision
- ARQQ Strong Buy
- NYXH Strong Buy
- Analyst Count
- ARQQ 1
- NYXH 4
- Target Price
- ARQQ $52.00
- NYXH $14.50
- AVG Volume (30 Days)
- ARQQ 292.9K
- NYXH 137.9K
- Earning Date
- ARQQ 05-19-2025
- NYXH 05-16-2025
- Dividend Yield
- ARQQ N/A
- NYXH N/A
- EPS Growth
- ARQQ N/A
- NYXH N/A
- EPS
- ARQQ N/A
- NYXH N/A
- Revenue
- ARQQ $293,000.00
- NYXH $4,680,609.00
- Revenue This Year
- ARQQ $1,818.77
- NYXH $342.98
- Revenue Next Year
- ARQQ N/A
- NYXH $195.80
- P/E Ratio
- ARQQ N/A
- NYXH N/A
- Revenue Growth
- ARQQ N/A
- NYXH 3.98
- 52 Week Low
- ARQQ $3.72
- NYXH $5.55
- 52 Week High
- ARQQ $52.79
- NYXH $12.21
- Technical
- Relative Strength Index (RSI)
- ARQQ 51.82
- NYXH 43.03
- Support Level
- ARQQ $15.00
- NYXH $6.03
- Resistance Level
- ARQQ $17.08
- NYXH $6.66
- Average True Range (ATR)
- ARQQ 1.05
- NYXH 0.30
- MACD
- ARQQ 0.14
- NYXH 0.17
- Stochastic Oscillator
- ARQQ 53.22
- NYXH 60.44
About ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product QuantumCloud. The firm operates in one segment that is, the provision of cybersecurity services via satellite and terrestrial platforms. The company operates and generates its revenue from UK.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.